RxDoctor Payments Data

Yungpo Wang, MD

Nephrology · Baldwin Park, CANPI 1639228919

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (32.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Vifor Pharma, Inc. accounts for 70.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $288 and has fallen 51.3% since, to $140 in 2023. That places this record below the midpoint for nephrology clinicians in CA, where the typical reported total is $1,018.

$613in general payments, 2019–2025

Across 12 payments — averaging $51.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$435
  • GSK$140
  • Pfizer$38
$241,454in research payments, 2019–2025

Across 4 payments — averaging $60,364 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Siemens Medical Solutions USA, Inc.$241K

What the payments were for

  • Consulting fees$14023%
  • Speaking & faculty fees$20033%
  • Food & beverage$19832%
  • Education$7512%

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vifor Pharma, Inc.7$435
GSK2$140
Pfizer3$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$613 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Medicare billing

Part B allowed, 2024
$4,609
Medicare patients
14
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$49,345
Sevelamer Carbonate70$18,344
Sodium Polystyrene Sulfonate38$4,704
Calcium Acetate38$4,339
Calcitriol237$3,926
Hydralazine Hcl117$2,603
Furosemide171$2,140
Amlodipine Besylate170$2,071
Losartan Potassium155$1,946
Nifedipine ErNifedipine37$1,669
Terazosin Hcl33$1,405
Potassium Chloride24$962
Lisinopril59$832
Isosorbide Mononitrate ErIsosorbide Mononitrate39$659
Bisoprolol Fumarate29$625

Paid to pharmacies, not to this prescriber.

Other nephrology in Baldwin Park

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →